CKLIFE SCIENCES (00775) announced an update on its investment in Dogwood Therapeutics, Inc. (Dogwood). On December 22, 2025, Dogwood reported positive interim results from its ongoing Phase 2b study of Halneuron® for chemotherapy-induced neuropathic pain (CINP).

An independent statistical review committee analyzed unblinded treatment data from 97 patients who completed the study. The findings indicated a statistically significant difference in pain improvement between patients treated with Halneuron® and those on placebo over the four-week trial period.

Dogwood highlighted that the preliminary efficacy of Halneuron® is noteworthy, as the interim cohort had an average CINP duration of five years, with 67% of eligible patients concurrently on stable doses of other chronic pain medications, including pregabalin, gabapentin, duloxetine, and opioids.

The study's overall dropout rate was approximately 4.4%, significantly lower than dropout rates observed in trials for other FDA-approved chronic pain therapies. Although the trial remains blinded, Dogwood stated these findings reinforce Halneuron®'s previously observed safety and tolerability profile from earlier clinical studies.

Based on current enrollment progress and interim results, Dogwood maintains its expectation to report preliminary outcomes by Q3 2026. The study is projected to achieve 80%-85% statistical power to detect treatment differences for Halneuron®.

Dogwood, a Delaware-incorporated biopharmaceutical company listed on Nasdaq Capital Market (ticker: DWTX), focuses on developing novel therapies for pain and neurological disorders. CKLIFE SCIENCES holds an approximate 83% indirect equity interest in Dogwood.